Table 2.
Hemodynamic, Vasopressor, and Exploratory Endpoint Data
| Low-NED (≤ 0.25 µg/kg/min) | HR (95% CI) | p-value | High-NED (> 0.25 µg/kg/min) | HR (95% CI) | p-value | |||
|---|---|---|---|---|---|---|---|---|
| Placebo (n = 48) | AT II (n = 56) | Placebo (n = 110) | AT II (n = 107) | |||||
| MAP response at hour 3, n (%) | 12 (25.0) | 44 (78.6) | < 0.001 | 25 (22.7) | 70 (65.4) | < 0.001 | ||
| MAP change from baseline to hour 3, mmHg | 2 (− 1–8) | 11 (7–16) | < 0.001 | 4 (− 1–10) | 11 (5–16) | < 0.001 | ||
| NED at hour 3, µg/kg/min | 0.21 (0.18–0.24) | 0.19 (0.15–0.23) | 0.01 | 0.46 (0.33–0.76) | 0.42 (0.28–0.67) | 0.20 | ||
| NED change from baseline to 3 h, µg/kg/min (mean ± SD) | − 0.01 ± 0.06 | − 0.02 ± 0.06 | 0.01 | 0.03 ± 0.31 | − 0.05 ± 0.12 | 0.01 | ||
| 7-d survival, % | 71 (56–82) | 87 (76–94) | 0.38 (0.15, 0.94) | 0.03 | 63 (53–71) | 63 (53–71) | 0.99 (0.63,1.53) | 0.94 |
| 7-d cumulative incidence of discontinuing RRT, % | 33 (12–72) | 59 (37–81) | 1.99 (0.55–7.24) | 0.29 | 11 (5–23) | 29 (16–48) | 2.97 (1.06–8.36) | 0.03 |
Unless otherwise noted, all values are expressed as median (IQR)
AT II, angiotensin II; MAP, mean arterial pressure; NED, norepinephrine-equivalent dose; RRT, renal replacement therapy; SD, standard deviation